NervGen announced the appointment of Keith Vendola as CFO, effective immediately. Vendola will lead the company’s financial strategy and operations, including capital markets activity, financial planning, corporate development and supporting strategic initiatives. Vendola joins NervGen from Wugen where he served as CFO.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NGEN:
- NervGen Pharma initiated with a Buy at H.C. Wainwright
- NervGen Pharma initiated with a Buy at Lucid Capital
- NervGen Pharma price target raised to $12 from $10 at Maxim
- NervGen Wins FDA Alignment for Phase 3 RESTORE Trial in Chronic Tetraplegia
- NervGen Pharma aligns with FDA on RESTORE study following End-of-Phase 2 meeting